And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest. We will take in another installment of our “Let’s-see-them-before-they-die” concert series, hang with a couple of our short people, manicure the official grounds, and take a nap or three. And what about you? This is the high season for summer getaways — will you be out and about, or planning to do so? You could also take advantage of the slightly slower pace and catch up on your reading. Or you could calculate how much the tariff wars will cost you. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Over the past year, National Securities analyst Jonathan Aschoff issued bullish notes on three biotechs, but did not mention his employer is owned by the same company, Fortress Biotech (FBIOP) (FBIO), that controls each biotech, Reuters reports. Fortress is the brainchild of longtime biotech entrepreneurs Dr. Lindsay Rosenwald and Michael Weiss. Owning National gives Fortress an in-house underwriter and private sales force of about 700 brokers, nearly a third of whom have been flagged by regulators, to help it raise money for its stable of nine ventures that are developing new drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy